Overview

Sebastian BioPharma is a preclinical-stage biotechnology company driven by a singular mission: to develop groundbreaking biologics that offer new therapeutic options for millions of cancer patients. The company utilizes compelling proof-of-concept data from multiple innovative therapeutic strategies and a versatile ‘plug-and-play’ antibody-oligonucleotide conjugate (AOC) platform to enhance the efficacy of immune checkpoint blockade (ICB) therapies for cancer treatment. Its lead product – iTAP – is currently advancing through the lead compound nomination stage.